asof | 2025-02-18

CRISPR Therapeutics AG (NASDAQ:CRSP) is at the forefront of the gene editing
industry, developing gene-based medicines for serious diseases through its
CRISPR/Cas9 platform. The company's diverse portfolio targets
hemoglobinopathies, oncology, regenerative medicine, and rare diseases, with
its lead product, CTX001, being an ex vivo CRISPR gene-edited therapy for
beta-thalassemia and sickle cell disease.
